An Observational study comparing the Efficacy and Safety between Intralesional Triamcinolone Acetonide(4mg/ml) And Modified Kligmans Formula in Treatment of Melasma
Not Applicable
- Conditions
- Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue
- Registration Number
- CTRI/2023/11/060279
- Lead Sponsor
- Aishwarya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed and consenting patients with melasma
Exclusion Criteria
1. Pregnant and lactating mothers
2. Patients with other facial hyperpigmented dermatoses, telangiectasia or Autoimmune disorder
3. Non consenting patients
4. Patients with unrealistic expectations
5. Patients who are already on treatment will be included after a wash out period of 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To study safety and efficacy of Modified Kligmans formula in treatment of Melasma. <br/ ><br>2. To study the efficacy and safety of Intralesional Triamcinolone Acetonide(4mg/ml) in treatment of Melasma <br/ ><br>3. To compare safety and efficacy of the above two in treatment of melasmaTimepoint: 2 months
- Secondary Outcome Measures
Name Time Method Melasma Assessment Severity Index <br/ ><br>and dermoscopic findingsTimepoint: 2 months